Table 2.
Average cost of Maintenance Regimen of each of the biologic DMARDs between 2012–2017.
| Drug Name | 2012 (Actual Cost) | 2017 (Actual Cost) | 2017 (2012 cost in 2017 dollars) | Percentage Increase in Adjusted costs from 2012 to 2017 |
|---|---|---|---|---|
| SELF ADMINISTERED DRUGS | ||||
| Golimumab | $52,506 | $93,961 | $59,877 | 57% |
| Adalimumab | $26,491 | $58,135 | $30,210 | 92% |
| Etanercept | $25,875 | $56,897 | $29,507 | 93% |
| Abatacept | $27,087 | $50,314 | $30,889 | 63% |
| Tocilizumab⁎⁎ | $27,056 | $47,155 | $30,854 | 53% |
| Tofacitinib | $25,616 | $46,377 | $29,212 | 59% |
| Certolizumab | $26,036 | $45,830 | $29,691 | 54% |
| OFFICE ADMINISTERED DRUGS | ||||
| Abatacept | $19,494 | $41,652 | $22,231 | 87% |
| Certolizumab* | $30,992 | $38,116 | $35,343 | 8% |
| Rituximab | $24,588 | $32,549 | $28,040 | 16% |
| Tocilizumab | $23,520 | $28,358 | $26,822 | 6% |
| Infliximab | $17,769 | $23,400 | $20,263 | 15% |
| Golimumab* | $23,138 | $23,804 | $26,836 | -8% |
⁎
indicates drugs that were approved in 2014;
⁎⁎
Tocilizumab was approved in October 2013 and hence figures of 2014 provided.